Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study

ESEMPiO Study Group

Research output: Contribution to journalArticlepeer-review

Abstract

AIM: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world.

PATIENTS & METHODS: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics.

RESULTS: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes.

CONCLUSION: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.

Original languageEnglish
JournalFuture Oncology
DOIs
Publication statusE-pub ahead of print - Nov 9 2018

Fingerprint Dive into the research topics of 'Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study'. Together they form a unique fingerprint.

Cite this